Oramorph

Active Ingredient:: Morphine Sulfate
Origin:: EU

Oramorph (Morphine Sulfate)

International sale not permitted. Listed for the domestic market and B2B only.

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as an oral formulation for oral use. It treats moderate to severe pain in adult patients who require strong analgesia.

GNH India supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

L. Molteni And C. Dei F.Lli Alitti Società Di Esercizio S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oramorph, an opioid analgesic, is employed to manage pain conditions where strong relief is needed.

Acute severe pain: provides rapid relief of intense postoperative or trauma‑related pain.
Chronic cancer pain: helps control persistent pain associated with malignant disease.
Severe neuropathic pain: reduces debilitating pain when other therapies are insufficient.

How It Works

Morphine sulfate acts as a full agonist at mu‑opioid receptors in the central nervous system. Binding to these receptors inhibits the release of neurotransmitters involved in pain transmission, leading to decreased perception of pain and altered emotional response to painful stimuli.

Side Effects

Morphine sulfate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

Nausea and vomiting: gastrointestinal upset often occurring after dosing.
Constipation: reduced bowel motility leading to hard stools.
Drowsiness or sedation: mild to moderate sleepiness.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure.
Allergic reactions: rash, itching, or anaphylaxis in sensitive individuals.

Precautions & Warnings

When prescribing Oramorph, clinicians should consider several safety measures.

Assess respiratory function: monitor for signs of breathing difficulty.
Monitor bowel habits: implement laxative regimen to prevent constipation.
Adjust dose in renal/hepatic impairment: reduce dosage as needed.
Avoid use in known hypersensitivity: discontinue if allergic reaction occurs.
Use only as directed: follow prescriber instructions closely.
Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Morphine sulfate can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid)

MAO inhibitors: risk of severe hypertension or serotonin syndrome.
CNS depressants (e.g., benzodiazepines): additive respiratory depression.
Respiratory depressants (e.g., barbiturates): heightened risk of fatal respiratory failure.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., erythromycin): may increase morphine levels.
Antihistamines: can enhance sedation.
Diuretics: may exacerbate hypotension.
Anticholinergics: may worsen constipation.

Frequently Asked Questions

Oramorph contains morphine sulfate and is used to relieve moderate to severe pain, such as postoperative pain, cancer‑related pain, or intense acute pain that cannot be managed with weaker analgesics.

Morphine sulfate binds to mu‑opioid receptors in the brain and spinal cord, inhibiting the release of neurotransmitters that transmit pain signals. This action reduces the perception of pain and alters the emotional response to painful stimuli.

The dosage of Oramorph is individualized and set by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. Exact dosing regimens should be obtained from a qualified healthcare professional.

Oramorph is classified as Pregnancy Category C, indicating risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. Morphine can pass into breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Oramorph, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Oramorph (morphine sulfate) is a prototypical mu‑opioid receptor agonist with a well‑established efficacy profile. Compared with newer opioids, it has a predictable pharmacokinetic profile but may require more careful monitoring for respiratory depression and constipation.

Oramorph should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and dispose of any unused medication according to local regulations.

Oramorph is administered orally, typically as a tablet or solution, according to the prescriber’s instructions. The patient should swallow the tablet whole with water or follow specific guidance for any liquid formulation.

The most serious risks include respiratory depression, severe hypotension, and potential for dependence or abuse. Patients should be monitored closely for signs of breathing difficulty, especially during dose initiation or after dose adjustments.

Oramorph should not be used by individuals with known hypersensitivity to morphine or other opioids, those who have recently taken MAO inhibitors, or patients with uncontrolled severe respiratory disorders. Contraindications must be evaluated by a qualified healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 07 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.